Evaluation of Lymphocyte Activation Gene3 (LAG-3) on Regulatory T Cells in Patients with Multiple Sclerosis by Intervention Effect of Fingolimod

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Immunology, School of Medicine AND Isfahan MS and Neuroimmunology Research Center AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Biology, School of Sciences, University of Isfahan, Isfahan, Iran

3 Assistant Professor, Department of Immunology, School of Medicine AND Isfahan MS and Neuroimmunology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 Professor, Department of Neurology, School of Medicine AND Isfahan MS and Neuroimmunology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

5 PhD Student, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

6 Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

7 PhD Student, Department of Epidemiology, School of Health and Nutrition, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Background: Regulatory CD4+Foxp3+ T cells (Tregs) play an important role in the prevention of autoimmune disease. It is also suggested that in multiple sclerosis (MS), a central nervous system disease, an aberrant Treg function may play a role. Lymphocyte activation gene3 (LAG-3) as a surface marker of Treg cells with negative regulation of the immune system can effectively encounter with effector lymphocytes. In this study, we evaluated frequency of CD4+Foxp3+LAG-3+ T cells before and after treatment with Fingolimod.Methods: Blood samples was obtained from 20 patients with multiple sclerosis before and after 1 months of Fingolimod treatment, and from 12 age-matched healthy control subjects. Then pripheral blood mononuclear cell (PBMCs) were isolated and the frequency of Treg cells expressing LAG-3 were determined by flowcytometry.Findings: The frequency of CD4+Foxp3+LAG3+ T cells in the peripheral blood of MS patients was increased when compared to baseline (P = 0.005).Conclusion: Our findings suggested that Fingolimod not only increases CD4+Foxp3+ Treg cells, but also is able to enhance expression of LAG-3 on their surface. This is a new finding for the Fingolimod on the immune system.

Keywords

References

  1. Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Clin Immunol 2012; 142(1): 2-8.
  2. Haas J, Hug A, Viehover A, Fritzsching B, Falk CS, Filser A, et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005; 35(11): 3343-52.
  3. Etemadifar M, Abtahi SH. Multiple sclerosis in Isfahan, Iran: past, present and future. Int J Prev Med 2012; 3(5): 301-2.
  4. Venken K, Hellings N, Liblau R, Stinissen P. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med 2010; 16(2): 58-68.
  5. Ohkura N, Hamaguchi M, Sakaguchi S. FOXP3+ regulatory T cells: control of FOXP3 expression by pharmacological agents. Trends Pharmacol Sci 2011; 32(3): 158-66.
  6. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6(4): 345-52.
  7. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity 2004; 21(4): 503-13.
  8. Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, Sakaguchi S, et al. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci U S A 2009; 106(33): 13974-9.
  9. Workman CJ, Wang Y, El Kasmi KC, Pardoll DM, Murray PJ, Drake CG, et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol 2009; 182(4): 1885-91.
  10. Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 2009; 229(1): 67-87.
  11. Zhang Z, Duvefelt K, Svensson F, Masterman T, Jonasdottir G, Salter H, et al. Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis. Genes Immun 2005; 6(2): 145-52.
  12. Portaccio E. Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. Core Evid 2011; 6: 13-21.
  13. Warnke C, Stuve O, Hartung HP, Fogdell-Hahn A, Kieseier BC. Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2011; 7: 519-27.
  14. Chiba K, Kataoka H, Seki N, Maeda Y, Sugahar K. Fingolimod (FTY720), the Sphingosine 1-Phosphate Receptor Modulator, as a New Therapeutic Drug in Multiple Sclerosis. Inflamm Regen 2011; 31(2): 167-74.
  15. Wu T, Zhang L, Xu K, Sun C, Lei T, Peng J, et al. Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo. Transpl Immunol 2012; 27(1): 30-8.
  16. Commodaro AG, Peron JP, Lopes CT, Arslanian C, Belfort R, Jr., Rizzo LV, et al. Evaluation of experimental autoimmune uveitis in mice treated with FTY720. Invest Ophthalmol Vis Sci 2010; 51(5): 2568-74.
  17. Lan RY, Ansari AA, Lian ZX, Gershwin ME. Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev 2005; 4(6): 351-63.
  18. Kasper LH, Haque A, Haque S. Regulatory mechanisms of the immune system in multiple sclerosis. T regulatory cells: turned on to turn off. J Neurol 2007; 254(1): I10-I14.
  19. Sato DK, Nakashima I, Bar-Or A, Misu T, Suzuki C, Nishiyama S, et al. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. J Neuroimmunol 2014; 268(1-2): 95-8.
  20. Camisaschi C, Casati C, Rini F, Perego M, De FA, Triebel F, et al. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 2010; 184(11): 6545-51.
Journal of Isfahan Medical School
Volume 34, Issue 387 - Serial Number 387
May and June 2016
Pages 701-706

Files

History

  • Receive Date: 15 December 2015
  • Revise Date: 06 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics